Table 2.
Clinical results of MAL-PDT in treatment of BCC.
| Authors | No. of Treated Lesions | Hystotype | Treatment Outcome | Follow-up (Months) |
|---|---|---|---|---|
| Soler et al., 2001 [74] | 350 | sBCC/nBCC | CR 88.57% | 36 |
| Horn et al., 2003 [80] | 123 (94 pts) | sBCCs | CR 92% | 24 |
| nBCCs | CR 87% | |||
| Foley et al., 2006 [77] | 131 | BCC | CR 75% (MAL-PDT) | NA |
| CR 27% (PDT + placebo) | ||||
| Eibenschutz et al., 2008 [83] | 14 < 50 mm | BCC | CR 95% | 6 |
| 40–49 mm | CR 66% | 36 | ||
| Li et al., 2010 [76] | 95 (47 pts) | sBCC | OR 75.8% | 24 |
| Fantini et al., 2011 [75] | 194 (135 pts) | OR 62% | ||
| sBCC | CR 82% | NA | ||
| nBCC | CR 33% |
CR: complete remission; OR: overall response; NA: not available.